Satellos Bioscience Inc.
No enriched coverage for $MSLE in the last 7 days.
No SEC Form 4 filings for $MSLE in the last 30 days.
See all $MSLE insider activity →Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) received a U.S. patent for forazapadin, its lead drug candidate for treating degenerative muscle diseases. The patent, valid until 2044, covers forazapadin and related compounds, strengthening the company's IP portfolio. Satellos plans to pursue FDA approval and list the patent in the Orange Book.
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) completed enrollment for its Phase 2 BASECAMP trial of forazapadin for Duchenne muscular dystrophy. The trial, involving 18 sites globally, aims to assess safety, tolerability, and muscle force improvement. Satellos plans to share topline data in Q1 2027, adjusting from earlier plans to compile a comprehensive dataset.
Satellos Bioscience (MSLE) received FDA clearance for forazapadin to treat facioscapulohumeral muscular dystrophy (FSHD). The company plans a Phase 2 study in Q4 2026, with FSHD Canada Foundation providing up to $5M in funding. Forazapadin is also in Phase 2 trials for Duchenne muscular dystrophy (DMD).
Recent MSLE coverage spans financial news, technology and market movers.
The patent grant adds a layer of protection for the company's flagship asset, likely supporting the stock price.
Enrollment completion removes a major execution risk and sets the path toward topline data in Q1 2027, likely supporting upside.
Positive regulatory step could boost stock on future data readouts.
Positive naming may boost investor confidence ahead of Phase 2 data.
Interim efficacy and safety signals in a Phase 2 trial can improve perceived disease-modifying potential and trial credibility.
AlphAI scores every news story that mentions MSLE with an AI model for sentiment and relevance, and aggregates insider trades from Satellos Bioscience Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) received a U.S. patent for forazapadin, its lead drug candidate for treating degenerative muscle diseases. The patent, valid until 2044, covers forazapadin and related compounds, strengthening the company's IP portfolio. Satellos plans to pursue FDA approval and list the patent in the Orange Book.
2 min readSatellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) completed enrollment for its Phase 2 BASECAMP trial of forazapadin for Duchenne muscular dystrophy. The trial, involving 18 sites globally, aims to assess safety, tolerability, and muscle force improvement. Satellos plans to share topline data in Q1 2027, adjusting from earlier plans to compile a comprehensive dataset.
2 min readSatellos Bioscience (MSLE) received FDA clearance for forazapadin to treat facioscapulohumeral muscular dystrophy (FSHD). The company plans a Phase 2 study in Q4 2026, with FSHD Canada Foundation providing up to $5M in funding. Forazapadin is also in Phase 2 trials for Duchenne muscular dystrophy (DMD).
2 min readSatellos Bioscience (MSLE) announced the WHO assigned the INN forazapadin to its lead drug candidate, SAT-3247, for treating DMD and other muscle diseases. The company expects to complete enrollment in the BASECAMP Phase 2 study by Q3 2026 and release data in Q4. It also plans to start a Phase 2 trial for FSHD by year-end. The stock closed at $9.18, up 2.00%.
1 min readA healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.
3 min readSatellos Bioscience (NASDAQ:MSLE) reported early results for SAT-3247 in its TRAILHEAD adult DMD study. In four participants, biceps brachii muscle fat fraction improved 3.7 points (49.7% to 46.0%) by day 140, with TE99c rising about 34% and creatine kinase down 38%. BASECAMP readout is expected in Q4.
4 min readSatellos Bioscience (NASDAQ: MSLE, TSX: MSCL) reported six-month interim TRAILHEAD data for SAT-3247 in four adults with Duchenne muscular dystrophy. Mean muscle fat fraction fell 3.7% (49.7% to 46.0%), TE99C effort rose about 34% (16.1 to 21.6 J/kg), CK fell 38% (2130 to 1315 u/l), and safety was favorable. A call is scheduled July 8.
6 min readInvestment bank Leerink Partners has initiated coverage on Satellos Bioscience Inc. (MSLE) with an "Outperform" rating and a $20 target price. This positive outlook by analysts highlights the biotechnology company's innovative technology platform. The report aims to provide professional research references for investors interested in Satellos Bioscience.
2 min read
